Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NASA Send Cells Into Space-
April 2, 2010 (PhysOrg.com) -- NASA scientists are sending three fundamental life science experiments onboard space shuttle Discovery in hopes of better understanding exactly how spaceflight affects cell growth and how cells fight off infections.
New Stem Cell Treatment - High standard German clinic treats degenerative diseases. Request info - www.xcell-center.com/StemCells
NASA scientists are sending three fundamental life science experiments onboard space shuttle Discovery in hopes of better understanding exactly how spaceflight affects cell growth and how cells fight off infections. Future astronauts on long-term space missions need to understand how wounds heal and cells become infected in space to prevent illnesses during space travel.
When space shuttle Discovery hurtles into orbit after its April 5 scheduled launch, in addition to the multi-purpose logistics module filled with science racks for the laboratories aboard the station it will carry seven astronauts, two Space Tissue Loss experiments and 16 mice as it rendezvous with the International Space Station.
"As we expand humanity's reach to other planets we must learn how to live in space for prolonged periods of time," said Eduardo Almeida, the Space Tissue Loss's Stem Cell Regeneration experiment principal investigator and scientist at NASA's Ames Research Center, Moffett Field, Calif. "Understanding how space affects stem cell health is critical to exploration because our health relies on normal tissue repair and regenerative functions."
Stem Cell Regeneration experiment will study how embryonic stem cells develop into specialized tissue types, or "differentiate" in space. The experiment will use mouse embryonic stem cells and embryoid bodies, or ball-shaped collections of embryonic stem cells, as a model to study the effects of microgravity on adult stem cells' ability to carry out their normal function of repairing and regenerating tissues. Scientists compare the embryoid body to an early stage of development in mammals because embryonic stem cells can differentiate into any of the body's many cell types.
In the weeks leading up to launch, scientists working on the Stem Cell Regeneration experiment at NASA's Kennedy Space Center, Florida, grew mouse embryonic stem cells and prepared them for flight. Scientists will take the embryonic stems cells grown in the laboratory and place them into bioreactors, which are installed into an incubator that fits into a shuttle middeck locker, where they will remain during flight.
"We are trying to get at the root cause of tissue degeneration in space," said Almeida. "We hope our research will help find preventive measures to address adult stem cell health in microgravity."
The second Space Tissue Loss (STL) experiment, STL-Immune, led by principal investigator Cheryl Nickerson, associate professor of life sciences at the Center for Infectious Diseases and Vaccinology in the Biodesign Institute at Arizona State University, will be the first fundamental biology experiment to conduct an in-flight infection of human cells using pathogenic bacteria. Nickerson's experiment will characterize the effect of microgravity on intestinal cellular responses before and after Salmonella infection during space flight.
"In addition, this experiment also closely monitors human cells giving us unique insight into conditions faced by astronauts during spaceflight, as well as how cells in our bodies normally behave or transition to disease caused by infection, immune disorders or cancer," said Nickerson. "Only by studying how cells respond to microgravity can we reveal important biological characteristics that are masked by normal gravity when using traditional experimental approaches on Earth." The Immune experiment will help scientists determine whether bacterial responses to spaceflight are also seen in human cells.
"Better understanding how microbes and human cells interact in space can lead to novel vaccines and therapeutics for the general public against infectious disease, as well as other human diseases," added Nickerson. "Our research has potential benefits and applications for life on Earth and astronauts on long-duration space missions."
Mouse Immunology, the third space-based experiment, will study the influence of microgravity on mice immune systems. The experiment's principal investigator, Millie Hughes-Fulford, former NASA astronaut and professor in the Departments of Medicine and Urology at the University of California, San Francisco will test whether an immune system response to a new infection or re-infection is affected by spaceflight.
"Mouse immunology will allow us to pinpoint which genes and pathways are or aren't working or performing well in space," said Hughes-Fulford. "We will examine all 8,000 genes of the mouse thymus cell to determine the molecular cause of a suppressed immune system." Before launch, half of the mice in both the group that will fly to space and the control group that will stay on Earth received white blood cells that had been inoculated with thymus cells, or white blood cells, that were exposed to a foreign protein challenge. The other half of the mice will not be exposed until immediately after they return from space. Scientists will analyze whether the mice that received white blood cells react differently than those that were not pre-exposed.
All three experiments are managed by the International Space Station Non-Exploration Projects Office at NASA Ames. The NASA Ames Flight Systems Implementation Branch and Space Biosciences Division developed and implemented the Mouse Immunology and Space Tissue Loss payloads, which were all funded by the Advanced Capabilities Division in the Exploration Systems Mission Directorate at NASA’s Headquarters, Washington.
Provided by JPL/NASA (news : web)
Stem Cells and Medical Tourism http://www.worldhealthtraveler.com/
You are very welcome. ;)
MBLTY still needs a chart. Please request it here: http://stockcharts.com/help/doku.php?id=support:feedback:symbol_request
Ask for it on otc since that is where it trades in the US.
Cord Blood America Signs License Agreement to Operate Stem Cell Collection Business in China
Date : 03/31/2010 @ 9:00AM
Source : PR Newswire
Stock : Cord Blood America (BB) (CBAI)
Quote : 0.0094 0.0 (0.00%) @ 8:33AM
Cord Blood America Signs License Agreement to Operate Stem Cell Collection Business in China
Cord Blood America Signs License Agreement to Operate Stem Cell Collection Business in China
PR Newswire
LAS VEGAS, March 31
LAS VEGAS, March 31 /PRNewswire-FirstCall/ --
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that it has signed a License and Cooperation Agreement for the processing and storage of umbilical cord blood in China with AXM Pharma, Inc. (Pink Sheets: AXMP).
AXM Pharma is a global pharmaceutical company focused on the production, marketing and distribution of pharmaceutical and nutraceutical products in China, where it owns a production facility which follows Chinese Good Manufacturing Practices. AXM Pharma has had a major presence in the Chinese pharmaceutical market for more than 6 years. The License Agreement terms include that AXM Pharma will provide the equipment, facilities and personnel in China necessary for business operations and will market the service in that nation.
AXM Pharma owns six buildings totaling more than 200,000 square feet of space on its 13 acre biotech campus in Shenyang, China, dedicated for this venture. CBAI believes this creates the world's largest cord blood bank, with a capacity of more than 2 million samples to start. AXM Pharma also has over 200 employees and 20 distributors to support plans for a rapid ramp up of the cord blood stem cell business.
Cord Blood America will grant to AXM a license to use its proprietary technology and know-how for the processing and storage of cord blood and CBAI will provide consulting and training. In return, CBAI will receive a 10% equity stake in AXM Pharma's stem cell subsidiary and an 8.5% royalty for all cord blood sales. As part of the license, Matthew L. Schissler, Cord Blood America co-founder and CEO, has been appointed to the Board of Directors of AXM Pharma.
"We are extremely excited about this deal. This is a major step, a key building block, toward becoming the globally dominant stem cell storage company, which is our goal. Building what we believe to be the world's largest cord blood bank, in the world's most populous country, is a very logical strategic move forward," said Mr. Schissler.
The companies plan on the lab to begin processing stem cell samples by January 1, 2011, subject to receipt of regulatory approvals.
ABOUT AXM Pharma
AXM (Pink Sheets: AXMP) is the parent company of AXM Shenyang. The company was founded in 2004 at Shenyang, China. Its mission is to become a premier China-based US GMP pharmaceutical manufacturer and distributor targeting and penetrating the markets of China. The company currently owns licenses and is capable to produce both prescription and nonprescription drugs. AXM Shenyang has the ability to produce 30,000,000 tubes for ointment, 500,000,000 tablets and 250,000,000 capsules annually. The company has six buildings totaling over 200,000 square feet that are built on more than 13 acres of campus. It has the technology of microbial fermentation which is used to produce testosaterone and testosaterone undecanoate. In 2007, AXM Shenyang was appointed to sell GM1 as exclusive distributor for Brazil. Currently AXM Shenyang has more than 200 people in marketing and distribution serving more than 20 provinces in China.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate,'' "believe,'' "expect,'' "future,'' "intend,'' "plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
SOURCE Cord Blood America, Inc.
I just posted the links to that post so that you can go back and read the letter to President Bush if you feel like it.
Here are links for my post #372, "A couple of interesting pieces of history:
Letter to President-Elect Obama (November 2009)
http://www.michaelwest.org/testimony/totheHonorableBarackObama.pdf
Letter to President Bush (2001) http://www.michaelwest.org/testimony/Nobel%20Laureates'%20Letter%20to%20President%20Bush%20(washingtonpost.com).pdf
very interesting
A couple of interesting pieces of history.
Letter to President Bush (2001) It’s a shame that President Bush ignored it.
Letter to President-Elect Obama (November 2009) To his credit, President Obama acted on it. His actions in this arena may end up bringing the cost of health care down while simultaneously improving it with new cures.
Here's letter to Obama:
To the Honorable Barack H. Obama, President-Elect of the
United States
Ten years ago the discovery of human embryonic stem cells
touched off one of the most controversial and yet promising
technologies of our generation. These cells likely possess the
capacity to differentiate into all of the cell types of the human body.
They offer possibilities to produce new lifesaving therapies by
supplying heart muscle cells, dopaminergic neurons, and pancreatic
cells that could be used to rebuild the heart after a heart attack, the
brain of a patient with Parkinson’s disease, or glucose regulation in
children with diabetes. The landscape of diseases and medical
research problems potentially benefiting from this research is broad
and significant. However, for the last 10 years research in this field
has been slowed by restrictive federal funding policies and
consequent reservations in the private sector about committing
investment dollars in a field where the United States has no clear
policy.
In the coming decade our nation is facing significant economic
and social challenges, not the least of which are strains on our health
care system arising from the mounting health care costs associated
with the aging of the post WWII baby boom generation. As reported
by analysts associated with the stem cell initiative in California
(http://www.cirm.ca.gov/pub/pdf/EcoEval_091008_rpt.pdf) research
monies spent now to address novel and powerful new therapeutic
modalities such as those arising from stem cell research have
numerous potential economic benefits for the United States, leading
to advances in our understanding of not only methods of fashioning
valuable new therapies from stem cells but also deep insights into
cancer stem cells, developmental disorders, and the networks that
regulate gene expression.
While we recognize that legitimate ethical issues have been
raised by this research, it is important to understand that novel
technologies show the potential to produce “induced pluripotent stem
(iPS) cells” wherein no embryos or egg cells are utilized. In addition,
the majority of US citizens support hES cell research where the
embryos were destined to be discarded. Lastly, for the past 40 years
many of the common human virus vaccines including those directed
to measles, rubella, hepatitis A, rabies and poliovirus have been
derived from cells derived from human aborted fetal tissue, and these
vaccines have provided benefit to tens of millions of people. Thus,
there is a clear path to advancing the field of regenerative medicine in
a manner consistent with the values of the majority of Americans.
In 1961 President Kennedy displayed the vision of his
generation by focusing the financial resources of the United States
toward landing a man on the moon within a decade. A similar
visionary program in our time should be a 10-year program involving
academia and industry with a goal to translate the discovery of
human embryonic stem cells into actual safe and efficacious
therapies to save human life. We encourage you to make this a
priority for your administration. We could clearly demonstrate the
humanitarian spirit of our country by leading the world in applying the
best of mankind’s technologies in the alleviation of human suffering
including the millions of American patients who so desperately need
them.
Yours respectfully,
Kenneth J. Arrow*
Stanford University
Nobel Laureate, Economics, 1972
Baruj Benacerraf*
Dana-Farber Cancer Institute
Nobel Laureate, Physiology or Medicine, 1980
Robert N. Butler+
International Longevity Center
Founding Director, National Institute on Aging, National Institutes of Health
Mario R. Capecchi*
Howard Hughes Medical Institute, University of Utah School of Medicine
Nobel Laureate, Physiology or Medicine, 2007
Elias James Corey*
Harvard University
Nobel Laureate, Chemistry, 1990
Edmond H. Fischer*
University of Washington
Nobel Laureate, Physiology or Medicine, 1992
Robert W. Fogel*
University of Chicago Booth School of Business
Nobel Laureate, Economics, 1993
Corey Goodman+
Member National Academy of Sciences
Ronald M. Green+
Ethics Institute, Dartmouth College
Roger Guillemin*
Salk Institute for Biological Studies
Nobel Laureate, Physiology or Medicine, 1977
Herbert A. Hauptman*
Hauptman-Woodward Medical Research Institute, SUNY at Buffalo
Nobel Laureate, Chemistry, 1985
Leonard Hayflick+
University of California, San Francisco
James J. Heckman*
University of Chicago
Nobel Laureate, Economics, 2000
Dudley R. Herschbach*
Harvard University
Nobel Laureate, Chemistry, 1986
William Lipscomb*
Harvard University
Nobel Laureate, Chemistry, 1976
Marshall W. Nirenberg*
National Heart, Lung & Blood Institute, National Institutes of Health
Nobel Laureate, Physiology or Medicine, 1968
Eric S. Maskin*
Institute for Advanced Study
Nobel Laureate, Economics, 2007
George A. Olah*
University of Southern California
Nobel Laureate, Chemistry, 1994
Richard J. Roberts*
New England Biolabs
Nobel Laureate, Physiology or Medicine, 1993
Richard R. Schrock*
Massachusetts Institute of Technology
Nobel Laureate, Chemistry, 2005
Phillip A. Sharp*
Massachusetts Institute of Technology
Nobel Laureate, Physiology or Medicine, 1993
Hamilton O. Smith*
J. Craig Venter Institute
Noble Laureate, Physiology or Medicine, 1978
Robert M. Solow*
Massachusetts Institute of Technology
Nobel Laureate, Economics, 1987
James D. Watson*
Cold Spring Harbor Laboratory
Nobel Laureate, Physiology or Medicine, 1962
Michael D. West+
BioTime, Inc.
Robert W. Wilson*
Harvard-Smithsonian Center for Astrophysics
Nobel Laureate, Physics, 1978
+ Corresponding Author
* Nobel Laureate
NEW OUT!!!!Cord Blood America CEO Matthew Schissler Provides Details on Major European Acquisition
Date : 03/25/2010 @ 5:05AM
Source : PR Newswire
Stock : Cord Blood America (BB) (CBAI)
Quote : 0.0098 0.0 (0.00%) @ 2:05AM
Cord Blood America CEO Matthew Schissler Provides Details on Major European Acquisition
Cord Blood America CEO Matthew Schissler Provides Details on Major European Acquisition
PR Newswire
LAS VEGAS, March 25
LAS VEGAS, March 25 /PRNewswire-FirstCall/ --
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that its revenues from its new acquisition, stellacure GmbH, are projected to top $1 million in 2010.
"This amounts to 20 to 30 percent revenue growth for CBAI," said Matthew Schissler, CEO and co-founder of Cord Blood America, who was interviewed by analyst Francis Gaskins. The complete interview is available at: http://gaskinsco.com/cbai-3-24-10.mp3. Mr. Schissler said the acquisition was financed through monies previously raised and targeted specifically for acquisitions.
Cord Blood America announced this week that it has acquired 51 percent of stellacure (http://www.stellacure.com), headquartered in Hamburg, Germany, and the third largest cord blood banking service in that major European nation. stellacure operates in conjunction with the German Red Cross.
"This is absolutely the best company we could partner with, as a first step toward becoming a global leader in stem cell storage," Mr. Schissler said. "Their revenues were approximately $800,000 (U.S.) in 2009 and the German Red Cross, which also owns a portion of the company, is widely respected throughout Europe We believe this is one of the most significant stem cell storage companies in Europe and it already has begun to establish sales channels in Italy and Spain."
About Cord Blood America
Cord Blood America (OTC BB: CBAI) through its wholly owned subsidiaries, CorCell Companies Inc. and Cord Partners, Inc., markets a service to preserve the umbilical cord blood in a patented process for future use exclusively by the donating family. Located in Las Vegas, Nevada, CBAI's mission is to become the world's largest stem cell storage facility through acquisitions, diversification and organic growth. To find out more about CorCell visit our website at www.corcell.com. For investor information visit Cord Blood America, Inc. at www.cordblood-america.com.
CONTACT:
Paul Knopick
E & E Communications
(CYTX) Joe Feshbach's Highest Conviction Position: A Regenerative Medicine 'Game Changer'
http://seekingalpha.com/article/182039-joe-feshbach-s-highest-conviction-position-a-regenerative-medicine-game-changer
Courtesy of biomanbaba for pointing it out to me elsewhere.
Where America Stands: Stem Cell Research
http://www.cbsnews.com/video/watch/?id=6305502n&tag=related;photovideo
21 February 2010
A report filed by Agence France-Presse (AFP), a Paris-based news service, has confused cord blood banking with stem cell tourism:
A number of medical and scientific societies are taking steps to condemn "unproven stem cell therapies". Broadly speaking, these unproven therapies take place in countries with very little medical regulation, where clinics offer supposed miracle cures to tourists who pay tens of thousands of dollars. The patients receive stem cells from either umbilical cords or embryos.
The International Society for Stem Cell Research (ISSCR) ISSCR is issuing a report in April about stem cell tourism. The president of the ISSCR board, Irving Weissman, MD PhD, hosted a session on regenerative medicine at the Feb. 2010 annual meeting of the American Association for the Advancement of Science (AAAS).
The next day, Agence France-Presse (AFP) reported that Dr. Weissman described cord blood banks as "fraudsters" who "fleece" well-meaning parents. According to Dr. Weismman's biography, he was a co-founder of SyStemix in 1988, a company that worked on blood-forming stem cells before going out of business. He currently holds stock and consults for StemCells Inc. (Nasdaq: STEM), a company which just announced the first human neural stem cell transplant.
It is hard to believe that Dr. Weissman would dismiss cord blood banking, when according to the World Marrow Donor Association (WMDA) cord blood stem cells have provided 14,000 patient transplants world-wide since 1988. The embryonic stem cells which are the focus of ISSCR research have yet to treat a single human patient.
The AFP report suggests that Dr. Weissman was speaking against private cord blood banks that claim to provide families with biologic health insurance. Thanks to family banks, over 200 children have received their own cord blood as part of clinical trials that were approved by peer review boards.
Other statements:
CBR blog post
Retraction from ISSCR:
Response to Inaccurate Representation of Statements by ISSCR President
Last modified: 11.March 2010
Copyright 2000 - 2010 Frances Verter
U.S. stem cell expert is "hottest" researcher
Maggie Fox
WASHINGTON
Mon Mar 15, 2010 3:22pm EDTWASHINGTON (Reuters) - Rudolf Jaenisch, whose stem cell lab at the Massachusetts Institute of Technology has consistently broken new barriers in the field, is the world's "hottest" researcher, according to a survey by Thomson Reuters.
Health
The annual hot list from Thomson Reuters' Science Watch also names four genome experts at MIT and Harvard University's Broad Institute - Mark Daly, David Altshuler, and Paul I.W. de Bakker and Eric Lander.
Biostatistician Goncalo Abecasis of the University of Michigan, who has worked with the Broad team, also makes the top 12 list, as do Manchester University materials professors Andre Geim and Konstantin Novoselov, who discovered graphene, the two-dimensional form of carbon and who also worked on a new adhesive known commonly as gecko tape.
Shizuo Akira of Osaka University, named by Thomson Reuters as the hottest researcher in 2005 and 2006, is on the list for work on toll-like receptors - which are molecular doorways on immune cells.
Carlo Croce from Ohio State University makes the list for papers on cancer genetics, theoretical physicist Mikhail Katsnelson from Radboud University in Nijmegen, Netherlands, is on the list for work on condensed matter and computer scientist Ji-Huan He from Donghua University in Shanghai, China is there for work figuring out how to break down complex problems.
"Our annual roundup of researchers who have authored multiple Hot Papers allows us to recognize those who are leading scientific thought," said Christopher King, editor of Science Watch.
Thomson Reuters is the parent company of Reuters.
Science Watch uses Web of Science database to see which recent papers are being cited the most by other researchers.
"Many of the people featured in Chris King's list over the last decade are people that I would put money on to eventually win a Nobel Prize," Thomson Reuters' David Pendelbury, who compiles the company's annual Nobel predictions, said in a telephone interview.
"Hot papers are recently published papers, papers published in the past two years that are exceedingly highly cited right out of the blocks."
Jaenisch, who works with embryonic stem cells and the new cells made out of skin cells called induced pluripotent stem cells or iPS cells, had 14 of the most cited papers.
Scientists share their discoveries by writing studies called papers, which are published by journals. Other researchers read them, poke holes in them, try to replicate them and use them as the basis for their own studies.
Each time they do, they credit the original paper by citing it. Scientists who are cited frequently are highly influential and so is their field of study, Pendelbury said.
"You really have to be contributor in an area that is recognized as an important area to your fellow researchers," said Pendelbury. "It's an index, really, of which fields are of most interest."
Jaenisch's highly cited research looks at using iPS cells to study Parkinson's disease, sickle-cell anemia and other conditions.
press release
March 10, 2010, 3:04 p.m. EST · Recommend · Post:
Stem Cell Therapeutics Corp. Announces Publication of Phase IIa Stroke Data
CALGARY, ALBERTA, Mar 10, 2010 (MARKETWIRE via COMTEX) -- Stem Cell Therapeutics Corp. ("SCT" or the "Company") /quotes/comstock/11v!sss (CA:SSS 0.31, +0.04, +12.73%) wishes to announce the acceptance and publication of the paper entitled "The Beta-hCG + Erythropoietin in Acute Stroke ( BETAS) Study" by the journal "Stroke", on March 8, 2010. This paper was authored by Dr. Steven C. Cramer, from the University of California, Irvine, Dr. David Brown at Hoag Memorial Hospital Presbyterian, New Port Beach, Dr. Michael D. Hill of Foothills Hospital at the University of Calgary, and colleagues.
Dr. Allen Davidoff, VP of Product Development, commented as follows:
"The Stroke journal, published by the American Heart Association, is the top journal in the field of stroke research. Stem Cell Therapeutics is pleased to congratulate Dr. Steven C. Cramer, David Brown and Michael Hill for their efforts, acceptance and successful publication of this novel study by this highly respected, peer reviewed journal. Previously this work has only appeared in abstracts. This publication marks another important milestone in the development of NTx(R)-265 and provided the continued evidence of clinical safety and the foundation for the proof of concept study modified REGENESIS."
The BETAS study was designed as an open label trial to provide the first evidence that NTx(R)-265 could be safely administered to patients with acute ischemic stroke. A total of fifteen human subjects at three centers were administered a course of NTx(R)-265, sequential administration of human chorionic gandotropin (hCG) followed by erythropoietin (EPO), with the first dose at 24-48 hours after stroke onset. Patients were then monitored for 90 days. The study found that NTx(R)-265 appeared to be safe and patients showed improved clinical outcomes compared to published data on similar untreated stroke patients as well as a trend towards reduced infarct volumes over time in comparison to data previously described elsewhere. This preliminary examination of behavioural and motor domains highlighted priority areas that will be important to address in future studies. These results strongly support the safety of NTx(R)-265 and provide evidence for the achievability of this treatment in stroke.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company /quotes/comstock/11v!sss (CA:SSS 0.31, +0.04, +12.73%) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Stem Cell Therapeutics Corp.
Alan Moore, PhD
President and CEO
(403) 245-5495 ext. 224
amoore@stemcellthera.com
Stem Cell Therapeutics Corp.
Angelika Goncalves DaSilva
Operations Manager
(403) 245-5495 ext. 221
crampton@stemcellthera.com
www.stemcellthera.com
SOURCE: Stem Cell Therapeutics Corp.
mailto:amoore@stemcellthera.com
mailto:crampton@stemcellthera.com
http://www.stemcellthera.com
Copyright 2010 Marketwire, Inc., All rights reserved.
Most Popular
Most readMost commented 1.Mutual fund investors still wary of stocks
2.The rise and certain fall of the American Empire
3.Banks rally on M&A speculation
4.Crude oil ends up after supplies, China data
5.China's trade surplus shrinks further in February
Mutual fund investors still wary of stocks The rise and certain fall of the American Empire Banks rally on M&A speculation U.S. stocks gain as investors bid up banks Online community's uproar over Darwin's Rottweiler
Find a Broker Partner Center »
/quotes/comstock/11v!sss Stem Cell Therapeutics Corp. (SSS) /marketstate/country/CA The market is open7:46:39 pm The market is closed7:46:39 pm 0.31 Change +0.04 +12.73%
Volume 910,383 Real time quotes 0.340.320.300.280.2610a11a12p1p2p3p4p Add to portfolio ca:SSS Find a Broker Create alert /quotes/comstock/11v!sss Stem Cell Therapeutics Corp. (SSS) /marketstate/country/CA The market is open7:46:39 pm The market is closed7:46:39 pm 0.31 Change +0.04 +12.73%
Volume 910,383 Real time quotes Add to portfolio ca:SSS Find a Broker Create alert
Featured Stories
U.S. stocks gain as investors bid up banks
U.S. stocks edge higher for a second straight day thanks to a rally in the financial sector led by American...
Best Buy seeks first-mover advantage with 3D TV
Aiming to steal a beat on competitors, Best Buy's tied up with Panasonic to exclusively sell the Japanese...
Lexmark stock rebound follows moves up market
Search data reflect Yahoo concern, Microsoft gains
Yahoo may continue to lose its edge, analyst says
Yahoo Inc.’s “competitive position is weakening,” according to research published Monday by Morningstar...
More
BigCharts Virtual Stock Exchange FiLife.com WSJ Asia WSJ Europe WSJ Portuguese WSJ Spanish WSJ ChineseWSJ JapaneseWSJ RadioFinancial News
SEARCH
7:46 PM ESTMarch 10, 2010
/marketstate/country/us
New York
After/marketstate/country/uk
London
Closed/marketstate/country/jp
Tokyo
Open/marketstate/country/us
/marketstate/country/uk
/marketstate/country/jp
View All Latest News
/news/latest
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494667:44pAustralia unemployment rises to 5.3% in February
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494657:33pJapan shares rise as trading firms strengthen
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494647:31pStocks in focus for Thursday
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494637:30pHealth Minute: Urgent-Care Centers
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494627:30pBanks will find ways to replace overdraft fees
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494617:24pJapan reportedly to upgrade economic view
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494607:22pSouth Korea's Kospi rises 0.6% in early dealings
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494597:20pJapan's Q4 growth revised down to 0.9%
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494587:03pU.S. dollar buys 90.49 yen vs 90.55 late in NY
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494567:02pApril crude falls 23 cents to $81.86/bbl on Globex
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494577:02pApril gold climbs 30 cents to $1,108.40/oz on Glob
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494547:01pJapan's Nikkei up 0.6% at 10,624.74 in early trade
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494557:01pJapan's Topix Index climbs 0.6% to 928.15
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494536:59pStymied timers and gathering gold bugs
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494526:56pCORRECT: Japan's initial Q4 GDP growth was 1.1%
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494516:55pBREAKING
Japan Q4 GDP growth revised 0.9% vs initial 1.1%
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494496:53pJapan Q4 annualized growth revised to 3.8% vs 4.6%
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494476:43pAustralian shares inch up, with retailers higher
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494466:25pAfter the Bell from MarketWatch Radio Network
8c077dc4-5ad2-4f73-b9c3-a381c5fece05:1494456:23pMeasuring value of the dollar depends on view
Loading more headlines...
dow
/quotes/comstock/10w!i:dji/delayed
10,567+2.88
+0.03%nasdaq
/quotes/comstock/10y!i:comp
2,35918.27
0.78%s&p 500
/quotes/comstock/21z!i1:in\x
1,1465.17
0.45%Health Matters
12526407000001252641600000This Week in Japan
LISA TWARONITE
Fujitsu's 'antisocial' allegations
Fujitsu's disclosure incident this week shows how much Japan has changed — and also how much it remains the same./conga/kiosk/asia.html 63356
12410352000001241035200000Community
If 10 friends come over for the Super Bowl, you need $1,500 worth of 3-D glasses -- only one pair comes with the set. — NanobiojohnComment from the story:
Best Buy seeks first-mover advantage with 3-D | View comments
/conga/kiosk/community.html 63549
1252636200000
1252637100000
Health Matters
Kristen GERENCHER
Health reform needs sharper teeth
Aetna president says reform is coming, but the changes on the horizon don't go far enough.
• Hit by rate hikes, one patient fights back /conga/kiosk/health-care.html 63487 12420720000001242720000000Investment Strategies
Bankers' hour
Financials have advanced to face a significant technical test, reports Michael Ashbaugh.
• Technical Indicator: Daily premium newsletter
• Nasdaq claims key level Tuesday (sample)/conga/kiosk/investing.html 63131
12402432000001271779200000Market Junkie
A question of indexes
What's a dollar worth these days? That depends on which index you use to get the greenback's value.
• Foreigners buying fewer Treasurys?
63495
12410352000001241035200000Retirement
robert powell
Retirement boost
You need to boost your confidence in your retirement plan — and boost your savings plan.
• Top 10 places to retire | More retirement news/conga/kiosk/retirement.html 63476
12410352000001241035200000Taxes
Home sweet tax credit
The tax credit for home buyers has been extended and expanded.
• Tax tips for newlyweds
• More tax tools, tips and news/conga/kiosk/taxes.html 63489
12410352000001241035200000Video
The future is now
China and the U.S. are teaming up to make an electric car that combines technology from the two countries.
• China's BYD may build in California /conga/kiosk/video.html 63486
12518064000001251806400000British Economy
Labour of love
British Prime Minister Gordon Brown says the U.K.'s economic recovery remains fragile as his Labour Party prepares for elections.
• U.K. firms avoid 'hunted' role (First Take)/conga/kiosk/wildcard1.html 63360
12553992000001255399200000Weather
Reuters Forecast: More hurricanes
This year's storm season in the Atlantic could have several major hurricanes coming on land in the United States, meteorologists from AccuWeather warn. Hurricane season begins June 1.
/conga/kiosk/wildcard4.html 63581
MarketWatch.com Site Index
Topics
Help
Feedback
Newsroom Roster
Media Archive
Premium Products
Mobile
Podcasts
RSS
MarketWatch on Facebook
MarketWatch on Twitter
Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
License our Content
WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange
All Things Digital
MarketWatch Community
Financial News Online
WSJ.com Small Business
FiLife - Personal Finance
FINS.com - Propel your career
Copyright © 2010 MarketWatch, Inc. All rights reserved.
By using this site, you agree to the Terms of Service and Privacy Policy.
Intraday data provided by Interactive Data Real Time Services, a division of Interactive Data Corp. and subject to terms of use. Historical and current end-of-day data provided by Interactive Data Pricing and Reference Data. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Dow Jones Indexes(SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by Comstock and is at least 60-minutes delayed. All quotes are in local exchange time. Real-time last sale data provided by NASDAQ.
Beats Saline .Stem Cell Breast Augmentation - No Implants Required
Wednesday March 10, 2010
If Mother Nature did not bless you with bountiful breasts, yet you are wary of introducing a foreign material like breast implants into your body, you may soon have another option: stem cell breast augmentation.
Stem cells can be anything they want when they grow up, which is why they are so promising in the treatment of both congenital and degenerative disease. Stem cells found in liposuctioned fat are one of the latest areas being explored in stem cell research, and they are free of many of the ethical issues that come with stem cells gained by other means.
Here's the short version of how stem cell breast augmentation works: A surgeon performs liposuction on an area of your body where you could stand to lose a little excess fat. The suctioned fat is divided in half. One half of the fat has its stem cells extracted and purified. The stem cells are then added and mixed into the other half of the suctioned fat which is then reintroduced into the new site where more fullness is desired.
The extra stem cells serve two purposes:
1.to increase the amount of transplanted fat that survives and thrives
2.to encourage growth of more fat cells in the transplant area
The end result is of this is that you can actually grow your own bigger breasts. Your own fat and stem cells are used, and there is no need for the introduction of any foreign or artificial materials into your body. Bonus: You get a flatter tummy (or thinner thighs, as the case may be) as a result of the liposuction portion of the procedure.
Of course, all the usual risks of surgery still apply. And the procedure is still in the experimental stage, with no long term data available on its safety, effectiveness, or possible future effects on mammography or other types of breast cancer screeening.
Not quite ready to be a guinea pig for this new technology? Learn more more about enhancing your breasts the old-fashioned way with breast implants.
AMST There is a lot about this company that most don't realize yet. I'm still in the midst of doing some more digging and REALLY like what I'm finding.
I also contacted the company and told them I'm modding a board for their ticker and asked for a sample of the anti aging cream. Told them I want to be able to inform the investors as to whether or not it improves my skin. Product is supposed to be in the mail. Hopefully, it comes today. ;)
Stay tuned. ;)
Im going to have to take a closer look at this company.
First Person In The World Cured of Sickle Cell Due to Cord Blood Treatment - Worth a Watch(video)
http://www.corduse.com/press_room/index.php?page=news&id=4&act=view
ORLANDO, Fla., Nov. 13 -- Orlando is now home to what will quickly become the largest umbilical cord blood collection program in the nation. A new partnership between CORD:USE Cord Blood Bank and Winnie Palmer Hospital for Women and Babies will provide life-saving cord blood stem cells to people with blood diseases.
CORD:USE President and CEO, Dr. Edward Guindi said, "The CORD:USE Cord Blood Bank Collection Program at Winnie Palmer Hospital will be the largest of its kind in the nation, and will help to increase the inventory of available cord blood units, particularly units from underrepresented minority groups, for all those in need of a potentially life saving stem cell transplant."
The program will enhance Central Florida's rapidly growing reputation as a global center for new medical technologies and will be based at the third busiest birthing center in the country. "We are excited about being part of the CORD:USE Cord Blood Bank donation program and the opportunity to help save lives across the nation through the national registry," said Kathy Swanson, President, Winnie Palmer Hospital.
Cord blood is the stem cell rich blood that remains in the umbilical cord and placenta following birth. Stem cells are collected from the umbilical cord blood that would otherwise be discarded, so there are no ethical or moral dilemmas involved.
Florida U.S. Senator Mel Martinez states, "I supported the passage of The Stem Cell Therapeutic and Research Act of 2005 at the end of last year which aims to increase the national inventory of available cord blood units, and I am glad to see steps taken like the beginning of this program by CORD:USE Cord Blood Bank and Winnie Palmer Hospital."
Umbilical cord blood can save the lives of critically ill patients, treating over 65 different diseases including leukemia, lymphoma and sickle cell anemia. Umbilical cord blood stem cell transplants have already been performed in over 8,000 patients, saving thousands of patients who would have otherwise not had a chance of survival.
Dr. Jeffrey Chell, the CEO of the National Marrow Donor Program, states, "The use of cord blood has increased dramatically in the past few years in absolute numbers and in the increased percentage of adults being helped with cord blood. Whereas, four years ago, only 1% of the transplants facilitated by the NMDP were cord blood, today more than 20% of the transplants are cord blood. In the next few years, I envision the percentage moving to 50%. Also, in the past month, 1/3 of the transplants using cord blood were for adult patients."
Posted this morning by MrLong on CBAI board. Thanks... ;)
I'm extremely interested in seeing if it helps my skin. ;)
very interesting karin, ty
One of the stem cell companies has a stem cell facial cream that will be hitting the market soon. I'm waiting on a sample to try. I'll be doing before and after photos for myself and I'll let you guys know the results once I've been on it for a month. ;)
STEMs getting some movement today
:o)
More about adult stem cells:
http://www.cnn.com/video/?/video/health/2010/03/01/pkg.gupta.cord.blood.cnn?iref=24hours
Good find...I reposted it on another board.
VTIAF ibox updated.
Now, I'm really off the computer.
Have a great day everyone.
Cord Blood Banks are Not Stem Cell Clinics
PublicAffairs | 23 February 2010, 2:55 pm Thanks DEW!
A recent story filed by Agence France-Presse (AFP), a Paris-based news service, offered a very misleading perspective on the current state of cord blood banking as well as the legitimate medical use of cord blood stem cells.
In essence, the reporter failed to recognize the difference between overseas “stem cell clinics” offering “unproven cures” and accredited cord blood banks in the U.S. that are facilitating FDA-approved research using a child’s own cord blood stem cells for new medical uses.
The story focused on comments made by one stem cell researcher, Dr. Irving Weissman, at the annual meeting of the American Association for the Advancement of Science (AAAS). Dr. Weissman appropriately denounces the practices of non-accredited “stem cell clinics,” which are often based in foreign countries with poor medical regulations, that offer infusions of stem cells as definitive treatments for a wide range of conditions. Several medical bodies and institutions have raised concerns about the inability of these clinics to substantiate their medical claims as well as the risk they pose to patient safety.
This is very different from the scientifically-valid and regulatory-approved research occurring in countries like the U.S. where pioneering physicians are studying the use of a child’s own cord blood stem cells as treatments for type 1 diabetes(1) and cerebral palsy(2). In fact, just last week Medical College of Georgia announced a new FDA-approved clinical trial to evaluate the use of a child’s own cord blood stem cells to treat cerebral palsy. It’s important to know that participants in these clinical trials were eligible because they had access to their own, genetically-unique cord blood stem cells because their parents made the decision to privately bank them at birth.
The protocols for these clinical trials require participants to have access to their own cord blood stem cells because they provide a guaranteed biological tissue match, do not require preparatory therapies like chemotherapy, do not pose the immune complications of donor cell infusions, and eliminate the need for anti-rejection drugs which can create complications. In other words, using a child’s own cord blood stem cells allows researchers to explore the potential of these cells in a way that is safe for patients.
It’s also important to note, that cord blood stem cells have been used for more than two decades to treat nearly 80 conditions, including certain cancers, blood disorders and immune diseases. Furthermore, stem cell researchers and leading medical organizations recognize that cord blood stem cells have unique characteristics. In fact, the American College of Obstetricians and Gynecologists states that cord blood stem cells “offers several distinct advantages” over other sources of stem cells when used in treatments for these types of conditions(3).
_________________________________________________
(1)Clincialtrials.gov. Umbilical Cord Blood Infusion to Treat Type 1 Diabetes. University of Florida. http://clinicaltrials.gov/ct2/show/NCT00305344?term=cord+blood+and+diabetes&rank=1. Accessed February 2010.
(2)Clinicaltrials.gov. Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children. Medical College of Georgia. http://www.clinicaltrials.gov/ct2/show/NCT01072370?term=cerebral+palsy+and+cord+blood&rank=1. Accessed February 2010.
(3)ACOG Committee Opinion. Umbilical Cord Blood Banking. Obstetrics and Gynecology. 2008;111(2):475-477.
http://zikkir.com/health/68851
AmStem Corporation Announces Ticker Symbol Change to AMST Effective Today formerly SCII
http://www.streetinsider.com/Press+Releases/AmStem+Corporation+Announces+Ticker+Symbol+Change+to+AMST+Effective+Today/5375010.html
And, that's just in one state.
Canadian Multiple Sclerosis Patient Improves After Stem Cell Treatment18 Feb 2010 .Posted by Don Margolis
?Another multiple sclerosis (MS)patient from Canada is reporting improvements after adult stem cell treatment from Dr. Shimon Slavin in Israel. Brent Davidson, from Cochrane, Alberta, Canada, says the adult stem cells which improved his quality of life "wasn’t cheap, but it was worth every penny.”
Davidson followed in the footsteps of fellow Canadians and multiple sclerosis patients Louis Zylstra and Arndt Roehlig, who went to Dr. Slavin for the stem cell therapy using their own stem cells.
Before the stem cells:
* reduced cognitive functions
* needed a cane to walk
* daily fatigue and pain
After the stem cells were implanted:
* Cognitive functions returned
* No cane needed, now Davidson is running and playing tennis!
* Davidson says "5% of the pain" there was before the treatment
The cost of the stem cell treatment was about $30,000, but Davidson says it was well worth it. Another MS patient from the same city in Canada is now trying to raise money to go abroad for the stem cell treatment as adult stem cells are not available in Canada.
Well, I wouldn't have to write about Canadians MS patients going abroad if adult stem cell treatment was available in Canada. Unfortunately, this safe treatment with their own stem cells is not available to them. Therefore, Canadians must travel abroad and pay money out of their own pocket for treatment that actually helps them. I guess that "free" Canadian health care isn't so great if you actually have to use it.
Rasheda Ali to Discuss BrainStorm on Fox News Today
Date : 02/22/2010 @ 1:05PM
Source : Business Wire
Stock : BrainStorm Cell Therapeutics Inc. (BCLI)
Quote : 0.42 0.0 (0.00%) @ 9:45AM
Rasheda Ali to Discuss BrainStorm on Fox News Today
BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that Rasheda Ali, a member of BrainStorm’s advisory board and revered author and daughter of renowned boxer Muhammad Ali, will discuss BrainStorm and its upcoming ALS clinical trials on today’s Neil Cavuto program on Fox News between 4:00-5:00 PM EST.
On the program she will discuss Brainstorm’s research and advancements and how the ALS clinical trials that are expected to start at Hadassah Medical Center in the coming months will hopefully be the first step towards finding a cure for ALS.
About BrainStorm Cell Therapeutics, Inc. BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Prof. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's current focus is on ALS, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.
Safe Harbor Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.
Stem cell funding adds 514 jobs
Legislature considers O'Malley request for $12.4M next year
by Gazette Staff |
Featured Jobs
Executive Assistant National Lutheran Home & Vill.
MEDICAL ASST Silver Spring (nr 4 crnrs). Come joi.
RECEPTIONIST Pediatric Dental office seeking a fr.
Real Estate Silver Spring WORK WITH THE BEST Be t.
See all jobsMore NewsFood bank prepares pantry for ‘extremely heavy' demandsBook details history of Petersville, Brunswick black churchesSenior winter Olympic games include ice hockey, curling eventsCheverly native balances politics and artistryResidents remember ‘Silent Spring'The Maryland Stem Cell Research Commission is using a new report to bolster its appeal for at least level funding in next year's budget.
The study, conducted by Sage Policy Group of Baltimore, shows that the program, which grants millions in awards each year, mostly to university researchers, supports 514 jobs, both direct and indirect, in the state, with an average salary of $64,000. The program facilitates $71.3 million in business sales in the state, and the stem cell industry generates $2.7 million in state and local taxes annually, the study says.
The Maryland Technology Development Corp., which administers the stem cell fund program, commissioned the study.
Gov. Martin O'Malley (D) is seeking $12.4 million for the stem cell fund in fiscal 2011, the same amount appropriated for the current fiscal year. That's a significant decrease from just two years ago, when some $22 million was appropriated for research grants. Last year, the program received $18 million. In June 2008, before the recession took a serious bite out of the state's finances, O'Malley proposed spending $20 million a year under his Bio 2020 Initiative.
Lawmakers are currently considering stem cell research funding in the fiscal 2011 budget. The Senate Budget and Taxation Committee's Health, Education and Human Resource Subcommittee, chaired by Edward J. Kasemeyer (D-Dist. 12) of Columbia, had scheduled a hearing for Monday afternoon. Among those scheduled to testify were John M. Wasilisin, acting president and executive director of Tedco, and Dan Gincel, director of the stem cell research fund, both of whom also testified before a House subcommittee on Thursday to argue against any cuts. Neither Gincel nor Kasemeyer immediately returned phone calls seeking comment on Monday.
"The findings of this economic development analysis validate, on paper, what supporters of stem cell research in our state have been saying for years — that Maryland's investment in stem cell research is not only critical to advancing science, but to moving our state's economy forward," O'Malley said in a statement. "Without the Maryland Stem Cell Research Fund, more than 500 Marylanders would be without a job and millions of direct and indirect dollars in state revenue would be lost. In this uncertain economy, the continued investment in stem cell research remains sound and valuable."
The study was based on data from the stem cell fund's first two years, fiscal '07 and '08. In those two years, the program awarded 82 projects totaling $38 million to Maryland stem cell researchers.
All told, the program has awarded more than $56 million to fund 140 research grants. The lion's share of the grants has gone to researchers at Johns Hopkins University, with most of the rest going to University of Maryland scientists. Only a few have gone to private-sector researchers.
"The impressive results of this study support the work of the Maryland Stem Cell Research Commission and the goals of the Maryland Stem Cell Research Fund," Wasilisin said in the statement. "The fund has reached great milestones since its inception in 2006, including our program's stellar national reputation which attracts the best and brightest in the field to the State of Maryland. With the support of the Governor and the legislature, our greatest achievements are still to come and we look forward to the work that lies ahead."
The study, "Economic Benefits of Maryland's Stem Cell Program Already Apparent," is available at www.mscrf.org/_media/client/pdf/Sage_stem_cell_program_impacts_Final.pdf.
I'm so glad that a lot of headway is being made in non embrionic stem cell work so as not to be mired into controvery.
Public release date: 18-Feb-2010
[ Print | E-mail | Share ] [ Close Window ]
Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
NIH stem cell guidelines should be modified, UCSF team reports
A UCSF team, led by bioethicist Bernard Lo, MD, recommends that the National Institutes of Health ethics guidelines for embryonic stem cell research be modified to better protect the rights of individuals donating egg or sperm to patients undergoing in vitro fertilization.
The recommendation is reported in the February 19, 2010 issue of Science.
Third parties frequently donate sperm and egg, or "gametes," for patients attempting to create embryos in the in vitro fertilization clinic.
Under current practice in the United States, gamete donors sign a form giving the IVF patient unrestricted legal authority to determine how to dispose of any embryos that may be leftover following fertility treatments. Donor banks and IVF clinics are not required to brief gamete donors about the various options for disposition, which include donating the embryos for stem cell research, thereby enabling scientists to derive new human embryonic stem cell lines; discarding the embryos, or donating them to other IVF patients.
While many state, national, and international scientific committees and agencies have recommended that third-party gamete donors give formal "informed consent" for stem cell research with embryos remaining after infertility treatment, the NIH did not stipulate this requirement in its guidelines issued in March 2009. As these guidelines determine which human embryonic stem cell (hESC) lines may be studied under NIH research grants – which are expected to play a growing role in funding stem cell research – the ethical implications are significant, says Lo, chair of the UCSF Gamete, Embryonic Stem Cell Research Committee, members of which published the Science paper.
"We urge the NIH to revise its guidelines to require that gamete donors be advised that embryos containing their sperm or egg could be used for embryonic stem cell research, before they grant dispositional authority over embryos to the IVF patient," he says. "Because some gamete donors may not approve of embryonic stem cell research, we consider this the ethically appropriate position."
In their paper, the team recommends a process that is less complex than the detailed "informed consent" process carried out when IVF patients donate embryos for research. They suggest the disclosure to gamete donors may be made through oral discussion or brochures before donors sign a form authorizing the IVF patient to determine the disposition of embryos.
Importantly, says Lo, the gamete donors' instructions would not disrupt the IVF process. IVF patients would learn of a gamete donor's restrictions in advance of selecting embryos for IVF treatment, and could select other gamete donors if not satisfied with the donors' disposition restrictions.
The recommendation is consistent with that of the National Academy of Sciences and the International Society for Stem Cell Research says Lo, a member of the ethics committee of the ISSCR, and the co-chair of the Standards Working Group of the California Institute for Regenerative Medicine.
"It would be highly desirable to have consistency among standards and regulations," he says. "If such harmonization were achieved, many university Institutional Review Boards and other research oversight bodies would likely allow NIH-eligible human embryonic stem cell lines to be used for any otherwise acceptable hESC research."
"It's critical that we consider all parties involved in the creation of embryos and honor their wishes," says co-author Arnold Kriegstein, MD, PhD, director of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF.
"The field of human embryonic stem cell research offers enormous promise for patients suffering from devastating diseases. We want to build this field on an ethical foundation of which we can be proud."
Exceptions to the guideline could be justified for hESC lines already in existence if there were strong scientific reasons to use the cell lines and the third-party gamete donor had granted rights to the IVF patient to determine disposition of the embryos.
###
Other co-authors of the study were other members of the UCSF Gamete, Embryonic Stem Cell Research Committee: Lindsay Parham, an analyst in the Program in Bioethics; Marcelle Cedars, MD, professor of obstetrics, gynecology and reproductive health and director of the Division of Reproductive Endocrinology; Susan Fisher PhD, professor of obstetrics, gynecology and reproductive sciences and director of the UCSF Human Embryonic Stem Cell Center; Elena Gates MD, professor of obstetrics, gynecology and reproductive sciences, and director of the IVF Tissue Bank; Linda Giudice, MD, PhD, chair of the Department of Obstetrics, Gynecology and Reproductive Sciences; Dina Gould Halme, PhD, formerly of the UCSF School of Medicine Dean's Office; William Hershon JD, Disability Rights California; Radhika Rao JD, University of California, Hastings College of the Law; Clifford Roberts, DVM, interim associate vice-chancellor for research; and Richard Wagner MA, associate director, Human Research Protection Program.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
Related links:
Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF http://stemcell.ucsf.edu/
NIH Expands Definition of Human Embryonic Stem Cell Thanks Ed!
by Constance Holden on February 19, 2010 4:32 PM | Permanent Link
Email Print | More Previous Article Next Article The National Institutes of Health is slightly expanding its definition for what constitutes a human embryonic stem cell. Currently, for purposes of including cells in its stem cell registry, NIH guidelines define the cells as "derived from the inner cell mass of blastocyst stage human embryo." As proposed tomorrow in the Federal Register, the definition will cover "early stage embryos up to and including" the blastocyst stage.
The change has come primarily in response to an application by Advanced Cell Technology (ACT) of Worcester, Massachusetts. "We came to understand recently that there was interest in deriving cells from earlier-stage embryos," says NIH's Lana Skirboll. ACT wants to list on the registry five cell lines derived from the earlier, morula stage. Skirboll says that, in addition, three lines submitted by Harvard Medical School's George Daley were derived from embryos that hadn't reached blastocyst stage. Approval for them has been put on hold pending acceptance of the revised definition.
So far the registry has approved 40 lines. The change is a small one, Skirboll says; There is no change in ethical guidelines for deriving cells.
I understand, I have in on my stemcells list for a long time now, it has made some great moves
ty for mentioning it
:o)
It's just my opinion. And, it could take months. But, I have my money on it. ;)
thanks for the info, will put on active watch list
:o)
I fully expect it to move beyond that .50 from last major spike. They actually have marketable product for distribution. Many are still in the research phase. I'm betting they are also still in research, but, putting out product brings in revenues. ;)
Bye all. ;)
yeah, might be basing here, need a little more upside to be sure
stems so puzzling buddy, all the building tremendous news, and they all stagnate
SCII Information.... This is interesting:
Exciting New Treatments AmStem will be generating and monitoring new, improved Clinical Trials to validate and build upon the early successes of Histostem, which has an established pipeline of promising treatments that have already been tested on real patients, including many that are patented in Korea.
AmStem will focus on developing a novel Hair Restoration clinical trial, using a method that has already been applied for, and is imminently pending a major U.S. Patent.
Histostem is the only company in the world to have full KFDA approval to use its cord blood derived stem cells directly for the treatment of disease. Clinical trials have been in progress for over 2 years to treat intractable conditions such as Buerger’s Disease, Alzheimer’s and Liver Cirrhosis, as well as Diabetes Mellitus, Hair Restoration and ALS.
Posted by: Electric120_208 Date: Thursday, February 18, 2010 2:37:24 PM
In reply to: None Post # of 623
International patent references from the World Intellectual Property Organization.
1. CELL THERAPY OF SPINAL CORD INJURY WITH STEM CELL DERIVED FROM UMBILICAL CORD BLOOD
http://www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=41293198-KEY&TYPE_FIELD=256&IDB=0&IDOC=942132&C=10&ELEMENT_SET=B&RESULT=2&TOTAL=6&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=KR2005003949&QUERY=%28PA%2f%22han%2c+hoon%22%29+OR+%28IN%2f%22han%2c+hoon%22%29+
2. METHOD OF ISOLATING AND CULTURING MESENCHYMAL STEM CELL DERIVED FROM CRYOPRESERVED UMBILICAL CORD BLOOD
http://www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=41283237-KEY&TYPE_FIELD=256&IDB=0&IDOC=937616&C=10&ELEMENT_SET=B&RESULT=1&TOTAL=1&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=KR2004002716&QUERY=%28FP%2fMETHOD+AND+FP%2fOF+AND+FP%2fISOLATING+AND+FP%2fCULTURING+AND+FP%2fMESENCHYMAL+AND+FP%2fSTEM+AND+FP%2fCELL+AND+FP%2fDERIVED+AND+FP%2fFROM+AND+FP%2fCRYOPRESERVED+AND+FP%2fUMBILICAL+AND+FP%2fCORD+AND+FP%2fBLOOD%29+
3. METHOD OF ISOLATING AND CULTURING MESENCHYMAL STEM CELL DERIVED FROM UMBILICAL CORD BLOOD
http://www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=41293198-KEY&TYPE_FIELD=256&IDB=0&IDOC=937615&C=10&ELEMENT_SET=B&RESULT=6&TOTAL=6&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=KR2004002715&QUERY=%28PA%2f%22han%2c+hoon%22%29+OR+%28IN%2f%22han%2c+hoon%22%29+
4. TREATMENT OF BALDNESS WITH STEM CELL DERIVED FROM UMBILICAL CORD BLOOD
http://www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=41293198-KEY&TYPE_FIELD=256&IDB=0&IDOC=942407&C=10&ELEMENT_SET=B&RESULT=1&TOTAL=6&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=KR2005004237&QUERY=%28PA%2f%22han%2c+hoon%22%29+OR+%28IN%2f%22han%2c+hoon%22%29+
Stem Cell Therapy (SCII) is now AmStem Corporation and the change is reflected on ihub and SEC documents. ;)
Oddly, my Fidelity and IB accounts still show Stem Cell Therapy.
I'm really happy to have this one in both accounts. This should be a good year for it. ;)
BrainStorm Secures Funding to Conduct Clinical Trials
Date : 02/17/2010 @ 11:58AM
Source : Business Wire
Stock : BrainStorm Cell Therapeutics Inc. (BCLI)
Quote : 0.36 0.01 (2.86%) @ 8:05AM
BrainStorm Secures Funding to Conduct Clinical Trials
BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it has entered into agreements with three investors with each investing $500,000 for a total of investment of $1.5 million into BrainStorm. The agreements require the Company to issue to each of the three investors two million shares of the Company’s stock based on the thirty day average share price as of February 11, 2010 of $0.25 per share and one million warrants with an exercise price of $0.50 per share for a total issuance of six million shares and three million warrants.
Along with these investors, ACCBT will invest its remaining commitment of approximately $500,000 in the Company. Together, these investments provide BrainStorm with the necessary funds to conduct its upcoming Phase I/II ALS clinical trials.
“We are extremely pleased that we were able to secure these investments,” stated Rami Efrati, CEO of BrainStorm. “These investments show continued support and belief in BrainStorm. The funds allow us to proceed with our ALS clinical trials that we hope to begin in the coming months.” Neither the shares of common stock offered and sold in the private placement nor the shares of common stock underlying the warrants were registered under the Securities Act of 1933, and, therefore, such shares may not be offered or sold in the United States absent registration or an applicable exemption from registration. BrainStorm offered and sold the shares of common stock and warrants in reliance on the statutory exemption from registration in Section 4(2) of the Securities Act or 1933 and/or Regulation D and/or Regulation S promulgated thereunder. This press release is not an offer to sell or a solicitation of an offer to buy any securities of BrainStorm, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933.
About BrainStorm Cell Therapeutics, Inc. BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Prof. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's current focus is on ALS, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.
Safe Harbor Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.
PerkinElmer Launches New Health Screening Lab in India, Partners with MediScan Systems to Increase Availability of Maternal &...
Date : 02/17/2010 @ 8:00AM
Source : Business Wire
Stock : PerkinElmer, Inc. (PKI)
Quote : 21.59 0.0 (0.00%) @ 8:00AM
Free PerkinElmer, Inc. Annual Company Report
PerkinElmer Launches New Health Screening Lab in India, Partners with MediScan Systems to Increase Availability of Maternal &...
PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and their environment, today announced that it has expanded its fetal, maternal and neonatal health screening capability in India, with the inauguration of the PerkinElmer Health Sciences laboratory.
The new laboratory, located in Chennai, will feature PerkinElmer’s advanced technologies for diagnosing common and serious health issues in expecting mothers and babies in India, including prenatal testing for Down Syndrome and other genetic disorders, maternal testing for pre-eclampsia, diabetes, thyroid disorders, and infectious disease, and newborn testing for potentially fatal inherited and metabolic disorders.
Ann-Christine Sundell, president, Genetic Screening, PerkinElmer, said, “PerkinElmer is delighted to announce the opening of our new laboratory in Chennai which brings greater availability of fetal, maternal and newborn screening to mothers and children in India. Of the more than 25 million babies born annually in India today, only a small percentage have access to medical screening to detect and treat health issues. In partnership with local leaders in fetal medicine, we look forward to improving family health outcomes.” In support of the Company’s fetal and maternal health program, PerkinElmer is also proud to announce its collaboration with MediScan Systems, led by founder Dr. S. Suresh, a leading Fetal Medicine Specialist and sonologist in India. MediScan has recently been certified by Dr. Kypros Nicolaides, director of the Fetal Medicine Foundation UK, as the first official Fetal Medicine Foundation Training Center in India.
Dr. Suresh, director of MediScan Systems, said, “We are very excited about our partnership with PerkinElmer, because working together we can now bring the highest quality fetal and maternal health diagnostics to young Indian families all over India.” PerkinElmer India, a wholly-owned subsidiary of PerkinElmer, operates as a direct sales, service and marketing operation targeting India’s thriving life science and analytical instrumentation markets. PerkinElmer India serves approximately 1,500 customers across various industries, including pharmaceutical, government, environmental, petrochemical and chemical. The Company provides precision instrumentation, testing systems and components, software and services for a wide range of scientific and industrial laboratory applications. Its products are used in predictive diagnostics, personalized medicine and environmental monitoring. PerkinElmer India currently employs approximately 170 people in Bangalore, Baroda, Chennai, Hyderabad, Kolkatta, Mumbai, New Delhi, Pune and Thane.
About MediScan Systems MediScan is the first referral diagnostic ultrasound centre in South India and has grown into one of the largest tertiary referral centres for Fetal Medicine in the region. The centre performs about 25,000 scans and over 3,000 fetal diagnostic and therapeutic procedures per year. MediScan is one of the best recognized training centres providing international quality training in ultrasound since its inception.
About PerkinElmer, Inc. PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.8 billion in 2009, has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
Entest BioMedical Publishes Journal Article on Laser Activation of Stem Cells for Treatment of Chronic Obstructive Pulmonary Dis
Date : 02/17/2010 @ 8:10AM
Source : MarketWire
Stock : Entest BioMedical Inc. (BMSN)
Quote : 0.063 0.0 (0.00%) @ 2:05AM
Entest BioMedical Publishes Journal Article on Laser Activation of Stem Cells for Treatment of Chronic Obstructive Pulmonary Dis
SAN DIEGO, CA -- (Marketwire) -- 02/17/10 --
Entest BioMedical Inc. (OTCBB: ENTB) announced publication of its manuscript "Lasers, Stem Cells, and COPD" in the peer-reviewed Journal of Translational Medicine. The manuscript was a collaborative effort led by Entest that included researchers from the University of California San Diego, University of Utah, the Center for the Study of Natural Oncology, and Cromos Pharma Services. The paper may be freely accessed at: http://www.translational-medicine.com/.
"Entest's Regenerative Photoceutical approach as represented by our ENT-576? program offers the possibility of using laser light to direct stem cell homing and activation. To our knowledge this is the first description in the peer reviewed arena of treating COPD via this method," according to Dr. Feng Lin, principal investigator for Entest's COPD research.
Low level lasers have been utilized in medicine for decades with some being sold commercially in the United States under 510k exemption. Entest has identified applications for these low level lasers in potentially treating COPD in conjunction with stem cell therapy. Additionally, the Company has filed patent applications covering specific methods of using these devices to activate stem cells. Entest's proprietary ENT-576? program utilizes localized laser therapy along with the administration of a drug that mobilizes patient stem cells in the treatment of COPD.
David Koos, Chairman & CEO of Entest, stated, "COPD is the 4th largest cause of death in the United States and it is Entest's deep desire to make an impact on finding a cure for this condition. By openly communicating our developmental ideas in a scientific format we hope to stimulate and engage others to work with us on solving this terrible problem."
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576? is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD. Entest Biomedical, Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN).
About Bio-Matrix Scientific Group:
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.
Follow the Company's progress on Twitter:
http://twitter.com/Entest_BioMed
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact: Entest BioMedical Inc.
David R. Koos Chairman & CEO 619.702.1404 Direct 619.330.2328 Fax Email Contact www.EntestBio.com
Bio-Matrix Scientific Group Inc.
www.BMSN.us Email Contact
Bookmark With :
This board is primarily for companies into cord blood storage since control of inventory will control treatments in the future. Discussion of updates in the field of stem cells and regenerative medicine will also be found.
Stem Cells – An overview
http://www.youtube.com/user/rorygirl#p/c/C9DB8E6493B73432/8/mUcE1Y_bOQE
Regenerative Medicine: Re-Growing Body Parts
http://www.youtube.com/user/rorygirl#p/c/C9DB8E6493B73432/16/GwcT1ViM-hw
Regenerative Medicine: Pathways to Cure - Version 2.0
http://www.youtube.com/user/rorygirl#p/c/C9DB8E6493B73432/15/tQ41GrOIbkE
The Stem Cell Stock Index
http://www.stemdex.com/2009/07/stem-cell-stock-index.html
The Stem Cell Tracker
http://www.stemcelltracker.com/
Diseases NOW Being Treated by Repair Stem Cells
http://repairstemcells.org/Treatment/Diseases-Treated.aspx
Global Cord Blood Stem Cells Market to Hit US$15 billion by 2015
http://www.prlog.org/10453315-global-cord-blood-stem-cells-market-to-hit-us15-billion-by-2015.html
Following are just a few of the companies in this arena. Listings are in alphabetical order by ticker:
ACTC - http://investorshub.advfn.com/boards/board.aspx?board_id=5319
http://www.advancedcell.com/
--------------------
AMST, formerly SCII - http://investorshub.advfn.com/boards/board.aspx?board_id=120
http://amsteminc.com/
--------------------
BCLI – http://investorshub.advfn.com/boards/board.aspx?board_id=4829
http://www.brainstorm-cell.com/
--------------------
CBAI - http://investorshub.advfn.com/boards/board.aspx?board_id=3650
Websites:
http://www.cordblood-america.com
http://www.cordpartners.com
http://www.cord-blood-video.com
http://www.curesource.net
http://www.corcell.com
--------------------
CCEL - http://investorshub.advfn.com/boards/board.aspx?board_id=3965
http://www.cryo-cell.com
Cryo-Cell Mexico offers services in Mexico, Central America and Ecuador.
Asia Cryo-Cell Private Limited offers services in India.
C'elle distributor opportunity for doctors that specialize in female issues. See video:
http://www.celle.com/distributorVideo.aspx#
--------------------
CO - http://investorshub.advfn.com/boards/board.aspx?board_id=16014
http://www.chinacordbloodcorp.com
--------------------
ISCO - http://investorshub.advfn.com/boards/board.aspx?board_id=13281
http://www.internationalstemcell.com/index.html
--------------------
SSS.V - http://investorshub.advfn.com/boards/board.aspx?board_id=11538
--------------------
Last update 4.20.2010
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Rules of the board
Respect each other
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |